Actively Recruiting

Phase Not Applicable
Age: 21Years +
All Genders
NCT06689553

Percutaneously Delivered Automated Continual Fluid Removal System in Patients With Advanced Diuretic-Resistant Heart Failure

Led by Paragate Medical LTD · Updated on 2025-07-30

8

Participants Needed

3

Research Sites

65 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study aims to assess the feasibility, safety, tolerability and functionality of a percutaneously delivered automated continual fluid removal System in up to 8 patients with Heart Failure (HF) and diuretic resistance. Intervention: Implanted absorption chamber, connected to an external pump. Follow up: 6 months post activation.

CONDITIONS

Official Title

Percutaneously Delivered Automated Continual Fluid Removal System in Patients With Advanced Diuretic-Resistant Heart Failure

Who Can Participate

Age: 21Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 21 years of age or older
  • Life expectancy greater than 6 months
  • Diagnosed with Heart Failure, New York Heart Association (NYHA) class II-IV
  • More than 1 heart failure related admission in the last 12 months
  • Signs of fluid congestion such as pitting edema, jugular distension, body weight elevation, nocturnal dyspnea, respiratory rate changes, pulmonary congestion, pleural effusion, or ascites
  • Failure to achieve effective diuresis despite appropriate or increasing diuretic doses or combination therapy
  • Able to provide written informed consent
  • Ability to comply with study procedures and operate the device themselves or with regular caregiver support
  • Residence near the medical center to ensure easy access to hospital and home visits
  • Women of childbearing potential must use effective contraception while the device is implanted
Not Eligible

You will not qualify if you...

  • Any non-cardiac disease with life expectancy less than 1 year
  • Listed for solid organ transplantation
  • History or indication for mechanical circulatory support
  • Intravenous inotropes required in the last 3 months (except Levosimendan)
  • Immunocompromised conditions such as chronic steroid treatment or HIV
  • Insulin dependent diabetes with evidence of infection
  • Severe hyponatremia (serum sodium less than 120 mmol/l)
  • Serum albumin less than 2.5 g/dl
  • Estimated glomerular filtration rate (eGFR) less than 20 ml/min/1.73m2
  • Previous significant intra-abdominal surgery, severe abdominal adhesions, or intra-abdominal foreign body (except small inguinal mesh)
  • Large diaphragmatic hernia currently or within last 6 months, or surgically irreparable hernia
  • Six-minute walk test less than 100 meters on repeated tests
  • Severe or repeated cardiac-related ascites as judged by the principal investigator
  • Inflammatory or ischemic bowel disease such as Crohn's disease, ulcerative colitis, or frequent diverticulitis
  • Current gastrointestinal active infection like Clostridium difficile
  • Gastrointestinal hemorrhage within the last 4 months
  • Bacterial peritonitis episode within the last 24 months
  • More than 2 systemic or local infections in the last 6 months
  • Class B or C liver cirrhosis of non-cardiac origin
  • Body mass index less than 18.5 or greater than 40 with surgical risk
  • Contraindications to anesthesia, sedation, or percutaneous/laparoscopic surgery
  • Unsuitable for self-maintenance of home device setup
  • Presence of current cancer as judged by principal investigator
  • Presence of active implantable or body-worn devices that cannot be removed (excluding ICD/pacemaker)
  • Known hypersensitivity to Nitinol nickel/titanium alloy or brilliant blue
  • Pregnancy
  • Participation in another therapeutic clinical study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

University Clinical Centre of Serbia

Belgrade, Visegradska 26, Serbia, 11000

Actively Recruiting

2

University Clinical Hospital Medical Center "Bezanijska kosa"

Belgrade, Serbia, 11080

Actively Recruiting

3

Hospital Clínico Universitario de Valencia-España

Valencia, Spain, Spain, 17 46010

Not Yet Recruiting

Loading map...

Research Team

I

Inbal Eyal

CONTACT

N

Nitai Hanani

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here